Since the ThinPrep Pap test was approved by the FDA in 1996, more than 170 studies have demonstrated its benefits, including increased disease detection, reduction of equivocal diagnoses, improved specimen adequacy, adjunctive molecular testing and morphology assessment. These published, peer-reviewed studies involving hundreds of thousands of patients show a significant benefit in the ThinPrep Pap test compared to a conventional pap smear. These studies, conducted in 7 different countries over 4 continents, also consistently demonstrate improved specimen adequacy. Additionally, the ThinPrep Imaging system has been shown to provide further improvements in disease detection along with decreased false negative rates compared to manually reviewed ThinPrep Pap test slides.